Advocating for Patients

The Concerning Rise of Youth Vaping and What States Can Do to Help

Vaping is causing serious lung disease in many teens. Yet, youth vaping continues to rise at an alarming rate. State policies can help curb youth vaping. As part of our 2019 State Honor Roll™ of Asthma and Allergy Policies for Schools (SHR), we look at the rise of vaping among our youth and what states can do to reduce rates.

AAFA Releases 2019 State Honor Roll Report in Advance of Asthma Peak Week

Schools provide valuable education to students. But the very resource that is supposed to benefit our children can actually be a cause of asthma symptoms and allergic reactions. Some states have policies in place that protect children with asthma and allergies. These 15 states made our 2019 State Honor Roll™ of Asthma and Allergy Policies for Schools (SHR). See how your state ranks.

AAFA Meets With DOT to Advocate for Equal Rights for People With Asthma and Allergies on Planes

The Asthma and Allergy Foundation of America (AAFA) met with the Office of the General Counsel of the U.S. Department of Transportation (DOT). We spoke with members of their Office of Aviation Enforcement and Proceedings and Consumer Protection Division on behalf of people with asthma and allergies. We shared how critical it is that people with asthma and allergies who have to be on planes with emotional support animals have equal rights.

Be Part of a Project to Shape New Eczema Treatments

AAFA has joined with four other nonprofit organizations that serve people with eczema to launch “More Than Skin Deep.” This project will inform and shape the development of treatments for eczema. A main part the project is a patient-focused drug development (PFDD) meeting on Sept. 23, 2019, in Washington, D.C.

AAFA Elevates Patient Voice in ICER Review of New Peanut Allergy Treatments

On June 11, 2019, in Oakland, California, the Institute for Clinical and Economic Review (ICER) and its California Technology Assessment Forum (CTAF) met to assess the clinical effectiveness and value of treatments for peanut allergy. The review examined two new technologies to induce immune tolerance — Viaskin® Peanut (DBV Technologies) and AR101 (Aimmune Therapeutics) — as well as non-commercialized oral immunotherapy (OIT).

AAFA Applauds DOT Warning About Denial of Preboarding to Family With Food Allergies

AAFA applauds the warning the U.S. Department of Transportation (USDOT) issued to American Airlines in response to American Airline’s denial of the right to pre-board a family of a child with food allergies. However, AAFA calls on the USDOT and Congress to take even stronger actions to protect the rights of airline passengers with allergies and all disabilities.

Spread Awareness About Asthma and Allergies in One Click

May is National Asthma and Allergy Awareness Month. Join us as we raise awareness about asthma and allergies. More than 25 million people in the U.S. with asthma. Ten people die every day from asthma. But with the right education and treatment, the deaths are preventable. Together, we can educate others about the seriousness of asthma.

Post
×
×
×
×